#USA #biopharmaceuticals #Boulder #muscle diseases #Edgewise Therapeutics

Edgewise Therapeutics Reports on Inducement Grants

On April 1, 2026, Edgewise Therapeutics, Inc., a prominent biopharmaceutical company specializing in treatments for muscle diseases, disclosed that it has issued inducement stock options to new non-executive employees as part of their employment. This announcement, in accordance with Nasdaq Listing Rule 5635(c)(4), signifies a strategic move to attract and retain talent within the specialized field of muscle disease therapeutics.

Details of the Inducement Grants

The company granted options to acquire a total of 72,000 shares of its common stock, divided among four new employees. The exercise price for these options has been set at $32.46 per share, reflecting the closing price of Edgewise's stock as of the grant date, March 31, 2026. Vesting of these options will follow a structured timeline: 25% will vest on the first anniversary of each employee's start date, with the remaining shares vesting monthly thereafter, contingent upon the employees' continued service at the company.

This inducement package is part of Edgewise's 2024 Inducement Equity Incentive Plan, aimed at encouraging high-caliber professionals to join and support the mission of the company. The move is not just a recognition of talent but also a commitment to developing ground-breaking therapies that address serious muscle diseases, including muscular dystrophies and cardiac conditions.

About Edgewise Therapeutics

Edgewise Therapeutics is renowned for its innovative approach to muscle disease treatments, utilizing in-depth knowledge of muscle physiology to pioneer new therapeutic solutions. The company is actively advancing its clinical pipeline, which includes:

• - Sevasemten: An oral fast skeletal myosin inhibitor being evaluated in late-stage trials for Becker and Duchenne muscular dystrophies.
• - EDG-7500: A novel cardiac sarcomere modulator designed for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 development.
• - EDG-15400: Another innovative cardiac sarcomere modulator aimed at treating heart failure, which is presently undergoing Phase 1 trials.

These advancements underscore Edgewise's commitment to transforming the lives of patients grappling with debilitating muscle disorders. The company's team is driven by a shared mission to improve the quality of life for individuals and families affected by these severe conditions.

Potential investors and interested parties can follow Edgewise Therapeutics' developments through official channels such as their website and LinkedIn page. The company continues to maintain a transparent approach to its operations and tailors its strategies to align with its innovative objectives.

In conclusion, the recent inducement grants align with Edgewise Therapeutics' strategic goals, reinforcing the importance of retaining skilled employees who can contribute to the delivery of groundbreaking therapies. As the company progresses, stakeholders are encouraged to stay informed about the latest news and updates from Edgewise,
creating a robust dialogue in the realm of muscle disease treatment.